07:00 , Oct 11, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal muscular atrophy Calcitonin gene-related peptide (CGRP) In vitro and mouse studies suggest reducing CGRP expression could help treat spinal and bulbar muscular atrophy (SBMA)....
07:00 , Oct 11, 2012 |  BC Innovations  |  Targets & Mechanisms

Repurposing naratriptan

Japanese researchers have shown in mice that GlaxoSmithKline plc 's marketed migraine drug Amerge naratriptan could be repurposed to treat spinal and bulbar muscular atrophy. 1 The pharma is not saying if it will pursue...
07:00 , Jul 7, 2008 |  BioCentury  |  Product Development

Cleaner than triptans

Triptans are the drug of choice for migraine patients, but they have cardiovascular side effects that leave many healthy patients wary and make them contraindicated for patients with CV disease. Merck & Co. Inc. disclosed...
07:00 , Oct 29, 2007 |  BioCentury  |  Product Development

Tezampanel vs. triptans

Tezampanel vs. triptans...
07:00 , Oct 8, 2007 |  BioCentury  |  Regulation

Significant isn't meaningful

Despite meeting the primary endpoints in two Phase III trials, last week Frova frovatriptan was deemed not approvable to prevent menstrual migraine. In yet another sign that FDA is moving the goalposts on product approvals,...
07:00 , Oct 10, 2005 |  BC Week In Review  |  Company News

Allergan, GlaxoSmithKline sales and marketing update

AGN granted GSK development and commercialization rights for Botox in China and Japan. The botulinum toxin is approved to treat uncontrollable blinking, hemifacial spasm and cervical dystonia. AGN will receive an upfront payment and is...
08:00 , Feb 11, 2002 |  BioCentury  |  Finance

CNS franchises

CNS franchises...
08:00 , Dec 3, 2001 |  BC Week In Review  |  Clinical News

Triptans: Marketed

Researchers published in The Lancet results of a meta-analysis of 53 clinical trials of 7 triptans in 24,089 patients with migraine headaches. According to the analysis, rizatriptan, eletriptan and almotriptan gave patients the greatest relief...
08:00 , Nov 1, 1999 |  BC Week In Review  |  Company News

Glaxo Wellcome, Schwarz Pharma sales and marketing update

Schwarz will exclusively co-promote in Germany Glaxo's Naramig naratriptan, a 5HT1D agonist to treat migraines. Glaxo Wellcome plc, London, U.K.   Schwarz Pharma AG, Monheim, Germany   Business: Neurological  ...
07:00 , May 18, 1998 |  BioCentury  |  Strategy

Vanguard's headache

SmithKline Beecham 's decision to drop commercialization of Vanguard Medica Ltd.'s frovatriptan VML-251 oral selective 5HT1D receptor agonist has left VGD without a marketing partner for the migraine treatment, which has completed Phase III development....